Literature DB >> 11122802

In vitro chemosensitivity testing and mechanisms of drug resistance.

K Tewari1, A Manetta.   

Abstract

This article reviews the cellular mechanisms that confer biochemical and clinical resistance to antineoplastic agents used in the adjunctive treatment and palliation of metastatic ovarian cancer. The historical development of in vitro chemosensitivity testing is also reviewed, along with published experiences of various investigators with assays used in clinical ovarian cancer treatment programs. Finally, an investigational protocol for chemosensitivity testing is proposed.

Entities:  

Mesh:

Year:  1999        PMID: 11122802     DOI: 10.1007/s11912-999-0014-6

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  49 in total

1.  Further observations on the effects of cancer chemotherapeutic agents on the in vitro dehydrogenase activity of cancer tissue.

Authors:  M M BLACK; F D SPEER
Journal:  J Natl Cancer Inst       Date:  1954-04       Impact factor: 13.506

2.  Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results.

Authors:  P J O'Dwyer; T C Hamilton; R C Young; F P LaCreta; N Carp; K D Tew; K Padavic; R L Comis; R F Ozols
Journal:  J Natl Cancer Inst       Date:  1992-02-19       Impact factor: 13.506

Review 3.  Tumor chemosensitivity and chemoresistance assays.

Authors:  E Brown; M Markman
Journal:  Cancer       Date:  1996-03-15       Impact factor: 6.860

4.  Tumor chemosensitivity and chemoresistance assays.

Authors:  D H Kern
Journal:  Cancer       Date:  1997-04-01       Impact factor: 6.860

Review 5.  Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer.

Authors:  P Cortazar; B E Johnson
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

6.  Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid.

Authors:  P J O'Dwyer; F LaCreta; S Nash; P W Tinsley; R Schilder; M L Clapper; K D Tew; L Panting; S Litwin; R L Comis
Journal:  Cancer Res       Date:  1991-11-15       Impact factor: 12.701

7.  Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.

Authors:  R F Ozols; R E Cunnion; R W Klecker; T C Hamilton; Y Ostchega; J E Parrillo; R C Young
Journal:  J Clin Oncol       Date:  1987-04       Impact factor: 44.544

8.  Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro.

Authors:  L Kangas; M Grönroos; A L Nieminen
Journal:  Med Biol       Date:  1984

9.  Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.

Authors:  L Levin; R Simon; W Hryniuk
Journal:  J Natl Cancer Inst       Date:  1993-11-03       Impact factor: 13.506

10.  The clinical relevance of chemosensitivity testing in ovarian cancer.

Authors:  C G Taylor; J M Sargent; A W Elgie; F D Reid; P A Alton; J G Hill
Journal:  Cancer Detect Prev       Date:  1998
View more
  2 in total

Review 1.  Methods and goals for the use of in vitro and in vivo chemosensitivity testing.

Authors:  Rosalyn D Blumenthal; David M Goldenberg
Journal:  Mol Biotechnol       Date:  2007-02       Impact factor: 2.695

2.  In vitro chemosensitivity in ovarian carcinoma: Comparison of three leading assays.

Authors:  Burak Tatar; Gökhan Boyraz; İlker Selçuk; Alper K Doğan; Alp Usubütün; Zafer Selçuk Tuncer
Journal:  J Turk Ger Gynecol Assoc       Date:  2016-01-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.